Product Description
for the treatment of Staphylococcal infections of the skin. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01519492)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Affinium
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Skin Diseases, Bacterial|Wound Infection|Abscess|Communicable Diseases|Cellulitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01519492 |
NCT01519492 | P2 |
Completed |
Wound Infection|Skin Diseases, Bacterial|Communicable Diseases|Cellulitis|Abscess |
2012-08-01 |
2019-03-19 |